Haemate P (Human Coagulation Factor Viii, Human Von Willebrand Factor)

Haemate P is indicated for the management of bleeding episodes and peri‑operative prophylaxis in patients with specific clotting disorders.

• Treatment of acute bleeding in hemophilia A patients with factor VIII deficiency.
• Prevention of bleeding during surgical or dental procedures in hemophilia A.
• Management of bleeding episodes in von Willebrand disease types 1, 2, and 3.
• Long‑term prophylactic therapy to reduce frequency of spontaneous joint bleeds in severe hemophilia A.
• Supportive therapy in patients undergoing major trauma or invasive diagnostics when factor levels are low.

Adverse reactions reported with Haemate P reflect the typical safety profile of plasma‑derived clotting factor concentrates.

Common

• Mild infusion‑site reactions such as erythema, warmth, or tenderness.
• Transient headache or low‑grade fever.
• Nausea or mild abdominal discomfort.
• Temporary elevation of liver enzymes without clinical significance.

Serious

• Development of inhibitors (antibodies) against factor VIII, reducing treatment efficacy.
• Allergic reactions ranging from urticaria to anaphylaxis.
• Thromboembolic events, particularly in patients with pre‑existing risk factors.
• Transmission of viral infections, although modern manufacturing greatly reduces this risk.

Before prescribing Haemate P, clinicians should evaluate patient history and laboratory data to minimize risks associated with plasma‑derived products.

• Assess for prior development of factor VIII inhibitors.
• Review history of allergic reactions to blood products.
• Evaluate for active thrombotic disease or high risk of thrombosis.
• Monitor liver function tests periodically during long‑term therapy.
• Use caution in patients with hepatitis or HIV infection.
• Ensure appropriate dosing based on body weight and factor activity levels.
• Store and reconstitute according to manufacturer instructions to maintain product integrity.

Haemate P may interact with other agents that affect hemostasis or immune response, requiring careful management.

Avoid

• Concomitant use of pro‑coagulant agents such as activated factor VII or prothrombin complex concentrates unless clinically indicated.
• Administration with high‑dose aspirin or non‑steroidal anti‑inflammatory drugs (NSAIDs) that increase bleeding risk.
• Simultaneous infusion with large volumes of crystalloid solutions may dilute clotting factors and reduce efficacy.

Use with caution

• Concurrent immunosuppressive therapy may alter inhibitor development risk.
• Use with other plasma‑derived products may increase cumulative viral exposure.
• Combination with antifibrinolytic agents (e.g., tranexamic acid) should be monitored for synergistic clotting effects.